Multidomain Intervention Trial for Preventing Cognitive Decline among Older Adults with Type 2 Diabetes: J-MIND-Diabetes
- PMID: 39559873
- PMCID: PMC11573805
- DOI: 10.14283/jpad.2024.117
Multidomain Intervention Trial for Preventing Cognitive Decline among Older Adults with Type 2 Diabetes: J-MIND-Diabetes
Abstract
Background: No multidomain intervention trials have been designed for the prevention of cognitive decline in older adults with type 2 diabetes.
Objectives: To investigate the efficacy of a multidomain intervention in preventing cognitive decline in older adults with type 2 diabetes and cognitive impairment.
Design: Eighteen-month, multi-centered, randomized controlled trial.
Setting: Twelve hospitals in Japan.
Participants: Outpatients with type 2 diabetes aged 70-85 years with cognitive impairment.
Intervention: The multidomain intervention program includes management of metabolic and vascular risk factors, exercise, nutritional counseling, and promotion of social participation. Participants in the control group received usual care and treatment for type 2 diabetes.
Measurements: The primary outcome was the change in a composite score combining several neuropsychological tests from baseline to the 18-month follow-up. To assess the differences in cognitive changes between the intervention and control groups, a mixed-effects model for repeated measures was used.
Results: Between March 13, 2019, and May 8, 2020, 361 participants were screened, and 154 were randomly assigned to either the intervention group (n = 81) or the control group (n = 73). Finally, 110 participants completed the trial. The between-group difference in the composite score changes was 0.068 (95% confidence interval, -0.091 to 0.226). Analyses for secondary outcomes indicated a positive impact of the intervention on memory and indicated that the intervention led to changes in dietary habits with increased intakes of niacin and meat, along with weight reduction compared to the control group.
Conclusion: The multidomain intervention did not demonstrate efficacy in preventing cognitive decline. However, this trial provided proof-of-concept evidence that multidomain interventions may offer cognitive benefits and contribute to changes in dietary behavior and weight reduction in older adults with type 2 diabetes and cognitive impairment. These findings should be confirmed in future studies.
Keywords: Multidomain intervention; cognitive decline; diet; exercise; type 2 diabetes.
Conflict of interest statement
TSu declares a research fellowship from the Manpei Suzuki Diabetes Foundation and a grant from the Keiko-Yamasaki Memorial Funds. AA declares honoraria from Novo Nordisk Pharma Ltd, Sumitomo Parma Co. Ltd., and Ono pharmaceutical Co. Ltd. NI declares research grants and contracts from Terumo Co., Drawbridge Inc., Asken Inc., Daiichi-Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co. Ltd., Japan Tobacco Inc., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., MSD K.K., Ono Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., LifeScan Japan K.K., and Kowa Co. Ltd.; honoraria for lectures from Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co. Ltd., Mitsubishi Tanabe Pharma Corp., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., Eli Lilly Japan K.K., and Kyowa Kirin Co. Ltd. MOg declares honoraria for lectures from AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Kowa Co. Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co. Ltd., Daiichi-Sankyo Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Mitsubishi Tanabe Pharma Corp., Teijin Pharma Ltd., Terumo Co., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., and Novo Nordisk Pharma Ltd. Other authors declare no conflicts of interest.
Figures



References
-
- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018;14:88–98. 10.1038/nrendo.2017.151 - PubMed
-
- Srikanth V, Sinclair AJ, Hill-Briggs F, Moran C, Biessels GJ. Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol 2020;8:535–545. 10.1016/S2213-8587(20)30118-2 - PubMed
-
- Mattishent K, Loke YK. Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta-analysis. Diabetes Obes Metab 2016;18:135–141. 10.1111/dom.12587 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical